Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The ‘Oxford-Kay Kendall Leukaemia Fund Graduate Scholarship’ based at the MRC WIMM, will commence in 2023.


A new DPhil scholarship has been endowed in the Division of Medical Sciences to be based at the MRC Weatherall Institute of Molecular Medicine within the Radcliffe Department of Medicine. Thanks to support from the Kay Kendall Leukaemia Fund (KKLF) and matched funding from the University of Oxford, the scholarship will support students to pursue research into leukaemia.

Available to applicants showing exceptional academic merit, the scholarship will cover course fees and a maintenance grant for the duration of the students’ study. The first Oxford-Kay Kendall Leukaemia Fund Graduate Scholar is expected to start in the academic year 2023-24.

Professor KJ Patel, Director of the MRC Weatherall Institute of Molecular Medicine, said: 'We are delighted to receive this generous support from the Kay Kendall Leukaemia Fund to endow a DPhil scholarship. KKLF’s commitment to advancing research into all areas of leukaemia will enable us to attract the very best scholars to Oxford.’

Similar stories

Spin-out company Alethiomics launches

The enterprise will focus on developing targeted therapies for a specific family of blood cancers.

Interview with Excellence Award winner Dr Susan Shapiro

A member of the Oxford Centre For Haematology, Dr Shapiro, was recently interviewed by the Royal College of Pathologists.

Iron integral to the development of life on Earth – and the possibility of life on other planets

A collaboration between researchers at the MRC WIMM and Department of Earth Sciences uncovers the importance of iron for the development of complex life on Earth.

Strong cytotoxic T cell responses to an internal viral component are associated with mild COVID-19 disease

Study from the Dong Group reveals key differences in the adaptive immune responses of patients with mild vs. severe COVID-19, highlighting a potential new vaccine target.

New model for infant leukaemia announced

The breakthrough could lead to development of new treatments for infant Acute Lymphoblastic Leukaemia.